Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Xue, Shao An ^a   Gao, Liquan ^a   Ahmadi, Maryam ^a   Ghorashian, Sara ^a   Barros, Rafael D ^a   Pospori, Constandina ^a   Holler, Angelika ^a   Wright, Graham ^a   Thomas, Sharyn ^a   Topp, Max ^b   Morris, Emma C ^a   Stauss, Hans J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Antitumor therapy; CMV; EBV; High avidity CD4 T cells; TCR gene transfer; Virus associated cancer

Indexed keywords

CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8 ANTIGEN GENE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GENE; GENETIC CODE; HELPER CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; T LYMPHOCYTE RECEPTOR GENE; TUMOR REJECTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

EID: 84886944339     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22590     Document Type: Article

References (39)

1. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigenreactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163:507-13; PMID:10384155.
2. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74:8207-12; PMID:10933734; http://dx.doi.org/10.1128/JVI.74.17.8207-8212.2000.
3. Engels B, Cam H, Schüler T, Indraccolo S, Gladow M, Baum C, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003; 14:1155-68; PMID:12908967; http://dx.doi.org/10.1089/104303403322167993.
4. Fujio K, Misaki Y, Setoguchi K, Morita S, Kawahata K, Kato I, et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol 2000; 165:528-32; PMID:10861092.
5. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102:3530-40; PMID:12869497; http://dx.doi.org/10.1182/blood-2003-05-1524.
6. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2:957-61; PMID:11577349; http://dx.doi.org/10.1038/ni1001-957.
7. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003.
8. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171:3287-95; PMID:12960359.
9. Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006; 20:61-9; PMID:15978709; http://dx.doi.org/10.1016/j.blre.2005.05.001.
10. Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW, et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003; 170:2186-94; PMID:12574392.
11. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR genetransduced human T cells. Blood 2005; 106:3062-7; PMID:16020516; http://dx.doi.org/10.1182/blood-2005-01-0146.
12. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2:962-70; PMID:11577350; http://dx.doi.org/10.1038/ni1001-962.
13. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999; 20:180-3; PMID:10203716; http://dx.doi.org/10.1016/S0167-5699(99)01443-7.
14. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx.doi.org/10.1200/JCO.2010.32.2537.
15. + T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251.
16. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918.
17. Moss P, Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 2005; 5:9-20; PMID:15630425; http://dx.doi.org/10.1038/nri1526.
18. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110:2838-45; PMID:17609424; http://dx.doi.org/10.1182/blood-2007-05-091280.
19. Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF, et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010; 84:407-17; PMID:19846527; http://dx.doi.org/10.1128/JVI.01303-09.
20. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005; 175:4137-47; PMID:16148164.
21. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest 2011; 121:4043-55; PMID:21946257; http://dx.doi.org/10.1172/JCI57147.
22. Diekmann J, Adamopoulou E, Beck O, Rauser G, Lurati S, Tenzer S, et al. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement. J Immunol 2009; 183:1587-97; PMID:19587004; http://dx.doi.org/10.4049/jimmunol.0803441.
23. + T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J Immunol 2007; 179:3203-13; PMID:17709536.
24. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67:3898-903; PMID:17440104; http://dx.doi.org/10.1158/0008-5472.CAN-06-3986.
25. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66:8878-86; PMID:16951205; http://dx.doi.org/10.1158/0008-5472.CAN-06-1450.
26. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109:2331-8; PMID:17082316; http://dx.doi.org/10.1182/blood-2006-05-023069.
27. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 2010; 184:6223-31; PMID:20483785; http://dx.doi.org/10.4049/jimmunol.0902055.
28. Thomas S, Xue SA, Cesco-Gaspere M, San José E, Hart DP, Wong V, et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol 2007; 179:5803-10; PMID:17947653.
29. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985; 21:235-46; PMID:3872841; http://dx.doi.org/10.1007/BF00375376.
30. Willemsen RA, Sebestyén Z, Ronteltap C, Berrevoets C, Drexhage J, Debets R. CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10. J Immunol 2006; 177:991-8; PMID:16818755.
31. Kessels HW, Schepers K, van den Boom MD, Topham DJ, Schumacher TN. Generation of T cell help through a MHC class I-restricted TCR. J Immunol 2006; 177:976-82; PMID:16818753.
32. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184:5988-98; PMID:20427771; http://dx.doi.org/10.4049/jimmunol.1000189.
33. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A 2000; 97:5387-92; PMID:10779548; http://dx.doi.org/10.1073/pnas.080078297.
34. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23:349-54; PMID:15723046; http://dx.doi.org/10.1038/nbt1070.
35. Holler PD, Lim AR, Cho BK, Rund LA, Kranz DM. CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptidedependent activation. J Exp Med 2001; 194:1043-52; PMID:11602635; http://dx.doi.org/10.1084/jem.194.8.1043.
36. + T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007; 179:5845-54; PMID:17947658.
37. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008; 180:6116-31; PMID:18424733.
38. Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, et al. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 2010; 95:126-34; PMID:19679884; http://dx.doi.org/10.3324/haematol.2009.006486.
39. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 2005; 90:1415-21; PMID:16219579.